Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2014 Jul 9

PMID 25004099

Citations 38

Authors

Kenneth C McCullough

Isabelle Bassi

Panagiota Milona

Rolf Suter

Lisa Thomann-Harwood

Pavlos Englezou

Thomas Demoulins

Nicolas Ruggli

Affiliations

Soon will be listed here.

Abstract

Self-amplifying replicon RNA (RepRNA) possesses high potential for increasing antigen load within dendritic cells (DCs). The major aim of the present work was to define how RepRNA delivered by biodegradable, chitosan-based nanoparticulate delivery vehicles (nanogel-alginate (NGA)) interacts with DCs, and whether this could lead to translation of the RepRNA in the DCs. Although studies employed virus replicon particles (VRPs), there are no reports on biodegradable, nanoparticulate vehicle delivery of RepRNA. VRP studies employed cytopathogenic agents, contrary to DC requirements-slow processing and antigen retention. We employed noncytopathogenic RepRNA with NGA, demonstrating for the first time the efficiency of RepRNA association with nanoparticles, NGA delivery to DCs, and RepRNA internalization by DCs. RepRNA accumulated in vesicular structures, with patterns typifying cytosolic release. This promoted RepRNA translation, in vitro and in vivo. Delivery and translation were RepRNA concentration-dependent, occurring in a kinetic manner. Including cationic lipids with chitosan during nanoparticle formation enhanced delivery and translation kinetics, but was not required for translation of immunogenic levels in vivo. This work describes for the first time the characteristics associated with chitosan-nanoparticle delivery of self-amplifying RepRNA to DCs, leading to translation of encoded foreign genes, namely influenza virus hemagglutinin and nucleoprotein.

Citing Articles

mRNA vaccines: a new era in vaccine development.

Chandra S, Wilson J, Good D, Wei M Oncol Res. 2024; 32(10):1543-1564.

PMID: 39308511 PMC: 11413818. DOI: 10.32604/or.2024.043987.

New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.

Demoulins T, Techakriengkrai N, Ebensen T, Schulze K, Liniger M, Gerber M Methods Mol Biol. 2024; 2786:89-133.

PMID: 38814391 DOI: 10.1007/978-1-0716-3770-8_4.

An Investigation into the Effects of Processing Factors on the Properties and Scaling-Up Potential of Propranolol-Loaded Chitosan Nanogels.

Ho H, Day R, Craig D Pharmaceutics. 2024; 16(5).

PMID: 38794324 PMC: 11125439. DOI: 10.3390/pharmaceutics16050662.

RNA Combined with Nanoformulation to Advance Therapeutic Technologies.

Lima E, Dos Santos D, Souza A, Macedo M, Bandeira M, Junior S Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139761 PMC: 10745936. DOI: 10.3390/ph16121634.

Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses.

Liu Y, Li Y, Hu Q Vaccines (Basel). 2023; 11(7).

PMID: 37514957 PMC: 10383046. DOI: 10.3390/vaccines11071142.

References

He C, Hu Y, Yin L, Tang C, Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31(13):3657-66. DOI: 10.1016/j.biomaterials.2010.01.065. View

Hoerr I, Obst R, Rammensee H, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 1999; 30(1):1-7. DOI: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. View

Summerfield A, Guzylack-Piriou L, Schaub A, Carrasco C, Tache V, Charley B . Porcine peripheral blood dendritic cells and natural interferon-producing cells. Immunology. 2003; 110(4):440-9. PMC: 1783075. DOI: 10.1111/j.1365-2567.2003.01755.x. View

McCullough K, Bassi I, Demoulins T, Thomann-Harwood L, Ruggli N . Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles. Ther Deliv. 2012; 3(9):1077-99. DOI: 10.4155/tde.12.90. View

Python S, Gerber M, Suter R, Ruggli N, Summerfield A . Efficient sensing of infected cells in absence of virus particles by plasmacytoid dendritic cells is blocked by the viral ribonuclease E(rns.). PLoS Pathog. 2013; 9(6):e1003412. PMC: 3681750. DOI: 10.1371/journal.ppat.1003412. View

Pichon C, Midoux P . Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA. Methods Mol Biol. 2013; 969:247-74. DOI: 10.1007/978-1-62703-260-5_16. View

Varkouhi A, Scholte M, Storm G, Haisma H . Endosomal escape pathways for delivery of biologicals. J Control Release. 2010; 151(3):220-8. DOI: 10.1016/j.jconrel.2010.11.004. View

Vazquez-Calvo A, Saiz J, McCullough K, Sobrino F, Martin-Acebes M . Acid-dependent viral entry. Virus Res. 2012; 167(2):125-37. DOI: 10.1016/j.virusres.2012.05.024. View

Johansson D, Ljungberg K, Kakoulidou M, Liljestrom P . Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One. 2012; 7(1):e29732. PMC: 3251598. DOI: 10.1371/journal.pone.0029732. View

10.

Ruggli N, Tratschin J, Mittelholzer C, Hofmann M . Nucleotide sequence of classical swine fever virus strain Alfort/187 and transcription of infectious RNA from stably cloned full-length cDNA. J Virol. 1996; 70(6):3478-87. PMC: 190221. DOI: 10.1128/JVI.70.6.3478-3487.1996. View

11.

Lai Y, Wang C . Delivery strategies of melanoma vaccines: an overview. Expert Opin Drug Deliv. 2008; 5(9):979-1001. DOI: 10.1517/17425247.5.9.979. View

12.

Palucka K, Banchereau J, Mellman I . Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010; 33(4):464-78. PMC: 2975953. DOI: 10.1016/j.immuni.2010.10.007. View

13.

Rayner J, Dryga S, Kamrud K . Alphavirus vectors and vaccination. Rev Med Virol. 2002; 12(5):279-96. DOI: 10.1002/rmv.360. View

14.

Frey C, Bauhofer O, Ruggli N, Summerfield A, Hofmann M, Tratschin J . Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application. Vet Res. 2006; 37(5):655-70. DOI: 10.1051/vetres:2006028. View

15.

Hafez I, Maurer N, Cullis P . On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001; 8(15):1188-96. DOI: 10.1038/sj.gt.3301506. View

16.

Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2):505-22. DOI: 10.1016/j.jconrel.2012.01.043. View

17.

Mccullough K, Basta S, Knotig S, Gerber H, SCHAFFNER R, Kim Y . Intermediate stages in monocyte-macrophage differentiation modulate phenotype and susceptibility to virus infection. Immunology. 1999; 98(2):203-12. PMC: 2326918. DOI: 10.1046/j.1365-2567.1999.00867.x. View

18.

Collnot E, Ali H, Lehr C . Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012; 161(2):235-46. DOI: 10.1016/j.jconrel.2012.01.028. View

19.

Sharma R, Ghasparian A, Robinson J, McCullough K . Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. PLoS One. 2012; 7(8):e43248. PMC: 3419204. DOI: 10.1371/journal.pone.0043248. View

20.

Platta H, Stenmark H . Endocytosis and signaling. Curr Opin Cell Biol. 2011; 23(4):393-403. DOI: 10.1016/j.ceb.2011.03.008. View